Key result
Noncardiac surgery within 1 month after stenting for ACS was associated with a markedly increased 30-day MI risk compared to controls without coronary disease (10% vs 0.8%; OR 20.1, 95% CI 8.85-45.6).
Why the study?
The 30-day risk of MI and death after noncardiac surgery performed within 1 year after coronary drug-eluting stent implantation for ACS or stable angina pectoris, compared with patients without known CAD, required examination.
Does noncardiac surgery within 1 year after coronary drug-eluting stent implantation increase the 30-day risk of MI and death compared to surgical patients without known coronary artery disease?
Cohort
Does noncardiac surgery within 1 year after coronary drug-eluting stent implantation increase the 30-day risk of MI and death compared to surgical patients without known coronary artery disease?
Noncardiac surgery performed between 1 and 12 months after drug-eluting stent implantation for ACS or SAP carries a similar risk of MI and death as in patients without coronary artery disease, whereas surgery within 1 month of ACS stenting has a markedly increased MI risk.
Surgery <1 month post-ACS stenting was associated with high MI risk; leaves open optimal timing thresholds in observational data.
This study aimed to examine the 30-day risk of myocardial infarction (MI) and death in patients who underwent noncardiac surgery within 1 year after coronary drug-eluting stent implantation for acute coronary syndrome (ACS) or stable angina pectoris (SAP) and to compare it with the risk in surgical patients without known coronary artery disease. Patients with drug-eluting stent implantation for ACS (n = 2,291) or SAP (n = 1,804) who underwent noncardiac surgery were compared with a cohort from the general population without known coronary artery disease matched on the surgical procedure, hospital contact type, gender, and age. In patients with ACS, the 30-day MI risk was markedly increased when surgery was performed within 1 month after stenting (10% vs 0.8%; adjusted odds ratio [OR adj ] 20.1, 95% confidence interval [CI] 8.85 to 45.6), whereas mortality was comparable (10% vs 8%, OR adj 1.17, 95% CI 0.76 to 1.79). When surgery was performed between 1 and 12 months after stenting, the 30-day absolute risk for MI was low but higher than in the comparison cohort (0.6% vs 0.2%, OR adj 2.18, 95% CI 0.89 to 5.38), whereas the mortality risks were similar (2.0% vs 1.8%, OR adj 1.03, 95% CI 0.69 to 1.55). In patients with SAP, the 30-day MI risk was low but higher than in the comparison cohort (0.4% vs 0.2%, OR adj 1.90, 95% CI 0.70 to 5.14), whereas the mortality risks were similar (2.2% vs 2.1%, OR adj 0.91, 95% CI 0.61 to 1.37). In conclusion, patients with ACS and SAP who underwent surgery between 1 and 12 months after stent implantation had a risk for MI and death that was similar to the risk observed in surgical patients without coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Thim et al. (2021) conducted a cohort in Acute Coronary Syndrome or Stable Angina Pectoris. Noncardiac surgery within 1 year after coronary drug-eluting stent implantation vs. Matched surgical patients without known coronary artery disease was evaluated on 30-day risk of myocardial infarction (surgery within 1 month for ACS) (OR 20.1, 95% CI 8.85-45.6). Noncardiac surgery within 1 month after stenting for ACS was associated with a markedly increased 30-day MI risk compared to controls without coronary disease (10% vs 0.8%; OR 20.1, 95% CI 8.85-45.6).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: